BamSEC and AlphaSense Join Forces
Learn More

Avalo Therapeutics Inc. – Material Contracts

NASDAQ: AVTX    
Share price (8/17/26): $19.95    
Market cap (8/17/26): $1.070 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.6
from 10-Q 5 pages June 12, 2026 Jennifer Riley Re: Changes to Your Employment Agreement Dear Jennifer,
12/34/56
EX-10.5
from 10-Q 5 pages June 12, 2026 Paul Varki Re: Changes to Your Employment Agreement Dear Paul,
12/34/56
EX-10.4
from 8-K 6 pages June 12, 2026 Taylor Boyd Re: Changes to Your Employment Agreement Dear Taylor,
12/34/56
EX-10.3
from 8-K 6 pages June 12, 2026 Mittie Doyle Re: Changes to Your Employment Agreement Dear Mittie,
12/34/56
EX-10.2
from 8-K 6 pages June 12, 2026 Christopher Sullivan Re: Changes to Your Employment Agreement Dear Christopher,
12/34/56
EX-10.1
from 8-K 6 pages June 12, 2026 Garry Neil Re: Changes to Your Employment Agreement Dear Garry Neil,
12/34/56
EX-10.1
from 8-K 9 pages Avalo Therapeutics, Inc. Second Amended and Restated 2016 Employee Stock Purchase Plan Adopted by the Board of Directors: April 2, 2026 Approved by the Stockholders: June 2, 2026
12/34/56
EX-10.1
from 8-K 8 pages Milestone Buyout Option Agreement and Amendment to Agreement and Plan of Merger and Reorganization
12/34/56
EX-10.2
from 10-Q 22 pages Avalo Therapeutics, Inc. 2025 Inducement Award Plan Adopted by the Board of Directors: September 16, 2025
12/34/56
EX-10.1
from 8-K 14 pages September 29, 2025 Taylor Boyd Dear Taylor: On Behalf of Avalo Therapeutics, Inc., a Delaware Corporation (The “Company”), We Are Pleased to Formalize for You the Terms of Your Employment With the Company as Set Forth in This Agreement (The “Agreement”)
12/34/56
EX-10.1
from 8-K 3 pages Avalo Therapeutics, Inc. Non-Employee Director Compensation Policy Amended Effective June 17, 2025
12/34/56
EX-10.1
from 8-K 3 pages Avalo Therapeutics, Inc. Non-Employee Director Compensation Policy Amended Effective March 25, 2025
12/34/56
EX-10.14
from 10-K 8 pages Indemnification Agreement
12/34/56
EX-10.1
from 8-K 13 pages On Behalf of Avalo Therapeutics, Inc., a Delaware Corporation (The “Company”), We Are Pleased to Formalize for You the Terms of Your Employment With the Company as Set Forth in This Agreement (The “Agreement”). Please Note That This Offer of Employment Is Contingent Upon a Clearance of a Background Check and Two Satisfactory Professional References
12/34/56
EX-10.4
from 10-Q 3 pages Avalo Therapeutics, Inc. Non-Employee Director Compensation Policy Amended Effective July 1, 2024
12/34/56
EX-10.2
from 8-K 11 pages Avalo Therapeutics, Inc. Amended and Restated 2016 Employee Stock Purchase Plan Adopted by the Board of Directors: June 6, 2024 Approved by the Stockholders: August 13, 2024
12/34/56
EX-10.1
from 8-K 23 pages Avalo Therapeutics, Inc. Fourth Amended and Restated 2016 Equity Incentive Plan Adopted by the Board of Directors: June 6, 2024 Approved by the Stockholders: August 13, 2024
12/34/56
EX-10.1
from 8-K 13 pages June 1, 2024 Mittie Doyle, MD Dear Mittie
12/34/56
EX-10.2
from 8-K 2 pages Amendment to Employment Agreement
12/34/56
EX-10.1
from 8-K 13 pages Paul Varki Dear Paul: On Behalf of Avalo Therapeutics, Inc., a Delaware Corporation (The “Company”), We Are Pleased to Formalize for You the Terms of Your Employment With the Company as Set Forth in This Agreement (The “Agreement”). Please Note That This Offer of Employment Is Contingent Upon a Clearance of a Background Check and Two Satisfactory Professional References
12/34/56